Ipca is the biggest producer of the drug. Cadila Healthcare, based in Ahmedabad, too is a major player. Both are gearing up to meet the demand and have said there will be enough supplies.
On top of this, a combination hydroxychloroquine and azithromycin, a common antibiotic, is being considered.
Vadodara-based drug major Alembic is the domestic market leader with its brand Azithral, with an almost 30 per cent share.
Sources said the country’s apex health research body, the Indian Council of Medical Research (ICMR), had included the drug in its protocol for treating COVID-19. The ICMR, however, has not confirmed this.
Pankaj Patel, chairman of Cadila Healthcare, said the firm was producing 20 tonnes of Hydroxychloroquine per month, and had started ramping up production.
He said the country could make 100 tonnes of the drug per month immediately.
هذه القصة مأخوذة من طبعة March 23, 2020 من Business Standard.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة March 23, 2020 من Business Standard.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول
Ratan Tata: Picture perfect
Politeness is to human nature What Warmth is to Wax.
I chose DLF over Disneyland dream, says KP Singh
KP SPEAK: Gurugram remains a developing city; urban planning needs a long-term vision, the PM must set up a high-powered panel for it
REDISCOVERY OF INDIA
Indian collectors are reclaiming Colonial-era art created by foreigners as an intrinsic part ofthe country's history
Go for fund with large AUM, high credit quality and low cost
Liquid funds have offered an average return of 7.28 per cent over the past year.
Auto majors in slow lane on weak demand
TaMo, Maruti, SMIL stocks down up to 23% in 4 weeks; analysts say downside risk limited, an opportunity for long-term investors
Volume growth for NMDC to remain robust in H2FY25
NMDC's revenue in Q2FY25 came in at ₹4,900 crore (a rise of 23 per cent year-on-year or Y-o-Y), while it was down 9 per cent quarter-on-quarter (Q-o-Q).
CIEL HR to file draft papers for ₹450 cr IPO
CIEL HR Services (CIEL), which uses technology to provide human resources solutions, will soon file draft papers for an initial public offering (IPO) estimated to be around ₹450 crore in size, according to sources.
Angel funds see red in Sebi's new accredited investors-only proposal
The Securities and Exchange Board of India's (Sebi's) proposal to allow only \"accredited investors\" to invest in angel funds has raised concerns in some quarters, even as most fund managers believe the overall ecosystem was set for a boost.
CLSA does U-turn on China, ups India exposure after Trump win
Says India seen as more attractive investment destination due to its strong economic growth and relatively low exposure to trade risks
Unfazed by mkt fall, largecap, flexicap MF schemes shine in Oct
Both categories saw all-time-high inflows during the month
